Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts-Reference-Cited by-同舟云学术

Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts

Published:2020-02-04 Issue:5 Volume:189 Page:888-903
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Al‐Ali Haifa Kathrin¹^ORCID,Griesshammer Martin²^ORCID,Foltz Lynda³,Palumbo Giuseppe A.⁴,Martino Bruno⁵,Palandri Francesca⁶,Liberati Anna Marina⁷,Coutre Philipp⁸,García‐Hernández Carmen⁹,Zaritskey Andrey¹⁰,Tavares Renato¹¹,Gupta Vikas¹²,Raanani Pia¹³,Giraldo Pilar¹⁴,Hänel Mathias¹⁵,Damiani Daniela¹⁶^ORCID,Sacha Tomasz¹⁷^ORCID,Bouard Catherine¹⁸,Paley Carole¹⁹,Tiwari Ranjan²⁰,Mannelli Francesco²¹,Vannucchi Alessandro M.²¹

Affiliation:

1. Universitätsklinikum Halle Halle (Saale)Germany

2. Johannes Wesling Medical Center Minden University Clinic for Hematology, Oncology, Hemostaseology, and Palliative Care UKRUB University of Bochum Minden Germany

3. St Paul’s HospitalUniversity of British Columbia Vancouver BC Canada

4. Dipartimento di Scienze Mediche Chirurgiche e Tecnologie Avanzate “G.F. Ingrassia” University of Catania CataniaItaly

5. Azienda Ospedaliera “Bianchi Melacrino Morelli” Reggio CalabriaItaly

6. Department of Hematology/Oncology “Seràgnoli” Institute of HematologyUniversity of Bologna School of Medicine BolognaItaly

7. University of PerugiaAzienda Ospedaliera S. Maria Terni Italy

8. Charité – Universitätsmedizin Berlin Berlin Germany

9. Hospital General de Alicante Alicante Spain

10. Almazov National Medical Research Centre St Petersburg Russia

11. Universidade Federal de Goiás Goiás Brazil

12. Princess Margaret Cancer Centre Toronto ON Canada

13. Institute of Hematology, Davidoff Cancer Center Rabin Medical Center Petah Tikva, and Sackler School of Medicine Tel Aviv University Tel Aviv Israel

14. Miguel Servet University Hospital and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) Zaragoza Spain

15. Klinikum Chemnitz gGmbH Chemnitz Germany

16. University of Udine Udine Italy

17. Jagiellonian University Kraków Poland

18. Novartis Pharma S.A.S. Rueil‐Malmaison France

19. Novartis Pharmaceuticals Corporation East Hanover NJ USA

20. Novartis Healthcare Pvt Ltd Hyderabad India

21. Center for Research and Innovation of Myeloproliferative Neoplasms Azienda Ospedaliero‐Universitaria CareggiUniversity of Florence Florence Italy

Funder

Novartis Pharmaceuticals Corporation

Publisher

Wiley